JP2016526531A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526531A5
JP2016526531A5 JP2016518498A JP2016518498A JP2016526531A5 JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5 JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5
Authority
JP
Japan
Prior art keywords
dose
administered
viral particles
particles per
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016518498A
Other languages
English (en)
Japanese (ja)
Other versions
JP6797680B2 (ja
JP2016526531A (ja
Filing date
Publication date
Priority claimed from GB201310698A external-priority patent/GB201310698D0/en
Priority claimed from GB201405140A external-priority patent/GB201405140D0/en
Priority claimed from GB201406509A external-priority patent/GB201406509D0/en
Application filed filed Critical
Priority claimed from PCT/EP2014/062284 external-priority patent/WO2014198852A2/en
Publication of JP2016526531A publication Critical patent/JP2016526531A/ja
Publication of JP2016526531A5 publication Critical patent/JP2016526531A5/ja
Application granted granted Critical
Publication of JP6797680B2 publication Critical patent/JP6797680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016518498A 2013-06-14 2014-06-12 Ｂ型アデノウイルスのための投与計画および製剤 Active JP6797680B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201310698A GB201310698D0 (en) 2013-06-14 2013-06-14 Method
GB1310698.4 2013-06-14
GB201405140A GB201405140D0 (en) 2014-03-22 2014-03-22 Method
GB1405140.3 2014-03-22
GB1406509.8 2014-04-10
GB201406509A GB201406509D0 (en) 2014-04-10 2014-04-10 Method
PCT/EP2014/062284 WO2014198852A2 (en) 2013-06-14 2014-06-12 A dosing regime and formulations for type b adenoviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020151615A Division JP2020203932A (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Publications (3)

Publication Number Publication Date
JP2016526531A JP2016526531A (ja) 2016-09-05
JP2016526531A5 true JP2016526531A5 (https=) 2016-10-20
JP6797680B2 JP6797680B2 (ja) 2020-12-16

Family

ID=51162703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016518498A Active JP6797680B2 (ja) 2013-06-14 2014-06-12 Ｂ型アデノウイルスのための投与計画および製剤
JP2020151615A Pending JP2020203932A (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020151615A Pending JP2020203932A (ja) 2013-06-14 2020-09-09 Ｂ型アデノウイルスのための投与計画および製剤

Country Status (12)

Country Link
US (2) US11173186B2 (https=)
EP (2) EP3007711B1 (https=)
JP (2) JP6797680B2 (https=)
KR (3) KR20210054067A (https=)
CN (2) CN105431157A (https=)
AU (2) AU2014280123B2 (https=)
BR (1) BR112015030881A2 (https=)
CA (2) CA3176971A1 (https=)
IL (1) IL243071B (https=)
RU (1) RU2671558C2 (https=)
SG (1) SG11201510064WA (https=)
WO (1) WO2014198852A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
EP3610870A4 (en) * 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
CN118001307A (zh) * 2018-03-30 2024-05-10 藤堂具纪 肿胀发生抑制型溶瘤病毒
CA3156171A1 (en) * 2019-09-30 2021-04-08 Candel Therapeutics, Inc. CANCER TREATMENT BY COMBINED GENE-MEDIATED CYTOTOXIC IMMUNOTHERAPY AND ATR INHIBITOR
CN114469938A (zh) * 2020-10-27 2022-05-13 中国医学科学院药物研究所 化合物bix02189在制备抗流感病毒药物中的应用
CN114601838B (zh) * 2022-04-29 2023-10-27 广东龙帆生物科技有限公司 一种azd8055在制备用于抗腺病毒感染的药物中的用途
WO2024042231A1 (en) * 2022-08-26 2024-02-29 Universite De Namur Adenovirus-based adjuvants for cancer treatment
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
IL135507A0 (en) * 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1137792B9 (en) 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
CZ20013560A3 (cs) 1999-04-09 2002-01-16 Aventis Pharma S. A. Tekutý nebo zmrazený přípravek určený k uchování rekombinantních infekčních adenovirů
US7279318B1 (en) 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
AU2004260044B2 (en) 2003-07-18 2009-04-23 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
US7510868B2 (en) * 2004-05-26 2009-03-31 Paul Harden Chimeric adenoviruses for use in cancer treatment
GB0416487D0 (en) 2004-07-23 2004-08-25 Isis Innovation Modified virus
WO2006060314A2 (en) 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
RU2382884C2 (ru) 2006-07-10 2010-02-27 Александр Владимирович Дидин Сферическая объемная роторная машина и способ работы сферической объемной роторной машины
JP5448840B2 (ja) * 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
WO2010067041A1 (en) 2008-12-11 2010-06-17 Hybrid Biosystems Limited Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20140316369A1 (en) 2011-11-14 2014-10-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
AU2013255511B2 (en) 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
US20170313990A1 (en) 2014-08-27 2017-11-02 Psioxus Therapeutics Limited A process for the production of adenovirus
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7

Similar Documents

Publication Publication Date Title
JP2016526531A5 (https=)
RU2015152860A (ru) Режим введения и составы для аденовирусов типа в
Yasinjan et al. Immunotherapy: a promising approach for glioma treatment
Basak et al. Tumor-associated macrophages: an effective player of the tumor microenvironment
Zhu et al. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Kanagavelu et al. In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation
Huang et al. Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer
Seicean et al. New targeted therapies in pancreatic cancer
JP2012067116A5 (https=)
JP2019065028A5 (https=)
JP2016530280A5 (https=)
JP2017031213A5 (https=)
JP2013189456A5 (https=)
JP2020509024A5 (https=)
JP2015187125A5 (https=)
RU2015144666A (ru) Терапия для лечения рака, включающая антитела против клаудина 18.2
Frieboes et al. Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy
JP2016515586A5 (https=)
Karapetyan et al. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
JP2016501528A5 (https=)
JP2017503846A5 (https=)
Wang et al. The pros and cons of dying tumour cells in adaptive immune responses
Jiang et al. Low‐dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer
Warricker et al. The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
He et al. Role of tumor-associated macrophages in breast cancer immunotherapy